Graphic Packaging Holding Company will announce its third-quarter 2026 financial results on November 3 before the market opens, followed by a conference call at 10 a.m. EST accessible via webcast and phone. The company, known for sustainable consumer packaging, will also tentatively release its fourth-quarter and full-year 2026 results on February 2, 2027. Investors can access the webcast replay starting at 1 p.m. ET on November 3. This update provides insight into the company's ongoing financial performance and commitment to sustainability in packaging.
Graphic Packaging Holding Company's upcoming third-quarter 2026 earnings call is noted here with Pluang's Consumer Staples sector data for context. For readers following this sector, of 51 priced US stocks tradable on Pluang, 16 rose and 35 fell. Estee Lauder Companies Inc (EL) was at USD 90.26 with a 1-day change of -2.71% and 100% sell order activity, J M Smucker Co (SJM) was at USD 115.79 with a -2.62% change and 100% buy order activity, and Adecoagro SA (AGRO) was at USD 9.90 with a -2.37% change and 100% buy order activity, as of Oct 02, 2026 02:41 WIB.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
